Cellular and phenotypic characterization of canine osteosarcoma cell lines

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 262-270

  Legare, Marie E ^a   Bush, Jamie ^a   Ashley, Amanda K ^a   Kato, Taka ^a   Hanneman, William H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Abrams; Canine; Osteosarcoma; U2

Indexed keywords

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL STRUCTURE; CELLULAR PARAMETERS; COMPARATIVE STUDY; DOG; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; LUNG METASTASIS; NONHUMAN; OSTEOSARCOMA CELL; OXIDATIVE STRESS; PHENOTYPE; SKIN TUMOR; TUMOR GROWTH;

EID: 84865080432     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.262     Document Type: Article

References (24)

1. Boston SE, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ: Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). J Am Vet Med Assoc 2006;228(12):1905-8.
2. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Swedelnikova OA, Solier S, Pommier Y: gammaH2AX and cancer. Nat Rev Cancer 2008;8(12): 957-967.
3. Bretaud S, Allen C, Ingham PW, Bandmann O: p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 2007;100(6):1626-35.
4. Chen HC: Boyden chamber assay. Methods Mol Biol 2005;294:15-22.
5. Chun R, Garrett LD, Henry C, Wall M, Smith A, Azene NM: Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 2005;41(6):382-7.
6. DeMaria R, Miretti S, Lussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Biolatti B, Levine RA, Buracco P, DiRenzo ME: met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol 2009;18(3):399-408.
7. Ehrhart N, Dernell WS, Hoffman WE, Weigel RM, Powers BE, Withrow SJ: Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998;213(7):1002-6.
8. Fan J, Ren H, Jia N, Fei E, Zhou T, Jiang P, Wu M, Wang G: DJ-1 Decreases Bax Expression through Repressing p53 Transcriptional Activity. J Biol Chem 2008;283(7):4022-30.
9. Fitzpatrick CL, Farese JP, Milner RJ, Salute ME, Rajon DA, Morris CG, Bova FJ, Lurie DM, Siemann DW: Intrinsic radio-sensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell lines. Am J Vet Res 2008;69(9):1197-202.
10. Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH: Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol 2004;41(3):291-6.
11. Garzotto CK, Berg J, Hoffman WE, Rand WM: Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14(6):587-92.
12. Goorin AM, Abelson HT, and Frei E 3rd: Osteosarcoma: fifteen years later. N Engl J Med 1985;313(26):1637-43.
13. Kanaya N, Yazawa M, Goto-Koshino Y, Mochizuki M, Nishimura R, Ohno K, Sasaki N, Tsujimoto H: Anti-tumor effect of adenoviral vector-mediated p53 gene transfer on the growth of canine osteosarcoma xenografts in nude mice. J Vet Med Sci 2011; [Epub ahead of print].
14. Kato TA, Okayasu R, Bedford JS: Signatures of DNA double strand breaks produced in irradiated G1 and G2 cells persist into mitosis. J Cell Physiol 2009;219(3): 760-765.
15. Levine RA, Fleischli MA: Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000;37(1):54-61.
16. Levine RA, Forest T, Smith C: Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002;39(3):372-8.
17. Levine RA: Overexpression of the sis oncogene in a canine osteosarcoma cell line. Vet Pathol 2002;39(3):411-2.
18. Liptak JM, Dernell WS, Straw RC, Rizzo SA, Lafferty MH, Withrow SJ: Proximal radial and distal humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc 2004;40(6):461-7.
19. Mueller F, Fuchs B, and Kaser-Hotz B: Comparative biology of human and canine osteosarcoma. Anticancer Res, 2007;27(1A): 155-64.
20. Stokkel MP, Linthorst MF, Borm JJ, Taminiau AH, Paviuels EK: A reassessemtn of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Canc Res Clin Oncol 2002;128(7):393-9.
21. Tomer G, Cohen IJ, Kidron D, Katz K, Yosipavitch Z, Meller I, Zaizov R: Prognostic factors in non-metastatic limb osteosarcoma. Int J Oncol 1999;15(1):179-85.
22. Vander Griend RA: Osteosarcoma and its variants. Orthop Clin North Am 1996;27(3):575-81.
23. Withrow SJ, Liptak JM, Straw RC, Dernell WS, Jameson VJ, Powers BE, Johnson JL, Brekke JH, Douple EB: Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004;11(7):705-13.
24. Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991; (270):159-68.